ALPS Group Inc Ordinary Share (ALPS) Competitors

$1.15 -0.04 (-3.36%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$1.15 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALPS vs. CMPX, MGNX, PRQR, BNR, and AKBA

Should you buy ALPS Group Inc Ordinary Share stock or one of its competitors? ALPS Group Inc Ordinary Share's main competitors and comparable companies include Compass Therapeutics (CMPX), MacroGenics (MGNX), ProQR Therapeutics (PRQR), Burning Rock Biotech (BNR), and Akebia Therapeutics (AKBA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ALPS Group Inc Ordinary Share compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Compass Therapeutics had 2 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 3 mentions for Compass Therapeutics and 1 mentions for ALPS Group Inc Ordinary Share. Compass Therapeutics' average media sentiment score of 0.33 beat ALPS Group Inc Ordinary Share's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compass Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ALPS Group Inc Ordinary Share
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ALPS Group Inc Ordinary Share has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass Therapeutics$850K144.92-$66.49M-$0.47N/A
ALPS Group Inc Ordinary Share$4.86M7.50-$2.01M$1.300.88

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Compass Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Compass TherapeuticsN/A -49.93% -43.76%
ALPS Group Inc Ordinary Share N/A N/A N/A

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 25.5% of ALPS Group Inc Ordinary Share shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Compass Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market.

Compass Therapeutics currently has a consensus target price of $9.99, indicating a potential upside of 1,360.77%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Compass Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.76
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Compass Therapeutics beats ALPS Group Inc Ordinary Share on 9 of the 16 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

MacroGenics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market.

MacroGenics currently has a consensus target price of $8.50, indicating a potential upside of 333.67%. Given MacroGenics' stronger consensus rating and higher probable upside, analysts clearly believe MacroGenics is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MacroGenics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 25.5% of ALPS Group Inc Ordinary Share shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, MacroGenics had 3 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 4 mentions for MacroGenics and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 0.00 beat MacroGenics' score of -0.28 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MacroGenics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ALPS Group Inc Ordinary Share
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to MacroGenics' net margin of -45.37%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
MacroGenics-45.37% -246.62% -31.36%
ALPS Group Inc Ordinary Share N/A N/A N/A

ALPS Group Inc Ordinary Share has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$149.50M0.84-$74.62M-$0.81N/A
ALPS Group Inc Ordinary Share$4.86M7.50-$2.01M$1.300.88

Summary

ALPS Group Inc Ordinary Share beats MacroGenics on 9 of the 16 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to ProQR Therapeutics?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

ALPS Group Inc Ordinary Share has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 7 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 8 mentions for ProQR Therapeutics and 1 mentions for ALPS Group Inc Ordinary Share. ProQR Therapeutics' average media sentiment score of 0.61 beat ALPS Group Inc Ordinary Share's score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALPS Group Inc Ordinary Share
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ProQR Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -205.68%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ALPS Group Inc Ordinary ShareN/A N/A N/A
ProQR Therapeutics -205.68%-72.78%-36.77%

27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 25.5% of ALPS Group Inc Ordinary Share shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ProQR Therapeutics has a consensus price target of $7.60, indicating a potential upside of 630.77%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ProQR Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

ALPS Group Inc Ordinary Share has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALPS Group Inc Ordinary Share$4.86M7.50-$2.01M$1.300.88
ProQR Therapeutics$18.36M5.97-$47.73M-$0.44N/A

Summary

ProQR Therapeutics beats ALPS Group Inc Ordinary Share on 9 of the 17 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to Burning Rock Biotech?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 25.5% of ALPS Group Inc Ordinary Share shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ALPS Group Inc Ordinary Share has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Burning Rock Biotech had 3 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 4 mentions for Burning Rock Biotech and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 0.00 beat Burning Rock Biotech's score of -0.18 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALPS Group Inc Ordinary Share
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Burning Rock Biotech
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
ALPS Group Inc Ordinary ShareN/A N/A N/A
Burning Rock Biotech -13.60%-12.98%-8.59%

ALPS Group Inc Ordinary Share has higher earnings, but lower revenue than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALPS Group Inc Ordinary Share$4.86M7.50-$2.01M$1.300.88
Burning Rock Biotech$514.43M0.27-$7.92M-$0.87N/A

Summary

ALPS Group Inc Ordinary Share beats Burning Rock Biotech on 8 of the 13 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to Akebia Therapeutics?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

ALPS Group Inc Ordinary Share has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

In the previous week, Akebia Therapeutics had 8 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 9 mentions for Akebia Therapeutics and 1 mentions for ALPS Group Inc Ordinary Share. Akebia Therapeutics' average media sentiment score of 0.05 beat ALPS Group Inc Ordinary Share's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALPS Group Inc Ordinary Share
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Akebia Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Akebia Therapeutics has a consensus target price of $3.50, suggesting a potential upside of 807.91%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Akebia Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -22.60%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ALPS Group Inc Ordinary ShareN/A N/A N/A
Akebia Therapeutics -22.60%-156.59%-11.53%

ALPS Group Inc Ordinary Share has higher earnings, but lower revenue than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALPS Group Inc Ordinary Share$4.86M7.50-$2.01M$1.300.88
Akebia Therapeutics$236.20M0.45-$5.34M-$0.16N/A

27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 25.5% of ALPS Group Inc Ordinary Share shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ALPS Group Inc Ordinary Share and Akebia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get ALPS Group Inc Ordinary Share News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALPS vs. The Competition

MetricALPS Group Inc Ordinary ShareBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$36.43M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.69%
P/E Ratio0.8823.0732.5628.72
Price / Sales7.5015.358.005.34
Price / CashN/A21.9220.2520.77
Price / Book-0.074.124.343.51
Net Income-$2.01M-$24.08M$3.51B$394.12M
7 Day Performance-2.54%-9.85%-8.07%-8.97%
1 Month Performance-29.86%-12.77%-10.29%-11.61%
1 Year PerformanceN/A-7.99%-4.70%-11.21%

ALPS Group Inc Ordinary Share Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALPS
ALPS Group Inc Ordinary Share
1.0116 of 5 stars
$1.15
-3.4%
N/AN/A$36.43M$4.86M0.8893
CMPX
Compass Therapeutics
3.5083 of 5 stars
$0.82
-1.2%
$9.99
+1,118.5%
-86.0%$147.67MN/AN/A39
MGNX
MacroGenics
2.0471 of 5 stars
$2.29
-1.3%
$8.50
+271.2%
+40.0%$145.87M$175.14MN/A293
PRQR
ProQR Therapeutics
3.6063 of 5 stars
$1.36
+7.9%
$7.60
+458.8%
-49.5%$143.29M$18.36MN/A166
BNR
Burning Rock Biotech
0.7283 of 5 stars
$13.33
+0.7%
N/A-6.9%$140.21M$514.43MN/A667

Related Companies and Tools


This page (NASDAQ:ALPS) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners